Peripheral μ-opioid receptor antagonist
Naloxegol
Brand names: Moventig
Adult dose
Dose: 25mg PO OD on empty stomach (≥30 min before food); reduce to 12.5mg if not tolerated
Route: PO
Frequency: OD
Clinical pearls
- Opioid-induced constipation when laxatives fail
- Does not cross BBB
Contraindications
- Bowel obstruction
- Concurrent strong CYP3A4 inhibitors
- Severe renal impairment without dose adjustment
Side effects
- Abdominal pain
- Diarrhoea
- Nausea
- Headache
- Opioid withdrawal
- GI perforation (rare)
Interactions
- Strong CYP3A4 inhibitors (avoid)
- Other peripheral μ-antagonists
Reference: BNF; NICE TA651; SmPC; https://bnf.nice.org.uk/drugs/naloxegol/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Numeric Rating Scale (NRS) Pain Assessment and Management · Pain Management
- HINTS Plus (Central vs Peripheral Vertigo) · Vertigo / Dizziness
- Carpal Tunnel Syndrome-6 (CTS-6) Diagnostic Tool · Peripheral Nerve
- Peripheral Blood Stem Cell (PBSC) Collection Target Calculator · Stem Cell Transplant
Drugs
Pathways
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021